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Abstract
Background: Medication-induced tremor (MIT) is common in clinical practice and there are many medications/drugs that can cause or exacerbate tremors.
MIT typically occurs by enhancement of physiological tremor (EPT), but not all drugs cause tremor in this way. In this manuscript, we review how some common
examples of MIT have informed us about the pathophysiology of tremor.
Methods: We performed a PubMed literature search for published articles dealing with MIT and attempted to identify articles that especially dealt with the
medication’s mechanism of inducing tremor.
Results: There is a paucity of literature that deals with the mechanisms of MIT, with most manuscripts only describing the frequency and clinical settings where
MIT is observed. That being said, MIT emanates from multiple mechanisms depending on the drug and it often takes an individualized approach to manage MIT
in a given patient.
Discussion: MIT has provided some insight into the mechanisms of tremors we see in clinical practice. The exact mechanism of MIT is unknown for most medications
that cause tremor, but it is assumed that in most cases physiological tremor is influenced by these medications. Some medications (epinephrine) that cause EPT likely lead to
tremor by peripheral mechanisms in the muscle (b-adrenergic agonists), but others may influence the central component (amitriptyline). Other drugs can cause tremor,
presumably by blockade of dopamine receptors in the basal ganglia (dopamine-blocking agents), by secondary effects such as causing hyperthyroidism
(amiodarone), or by other mechanisms. We will attempt to discuss what is known and unknown about the pathophysiology of the most common MITs.
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Introduction
It is often difficult to determine if a medication has caused a tremor
or has simply enhanced a patient’s underlying tremor, given that
tremor is prevalent and occurs in all to some degree (physiological
tremor). In addition, patients often take multiple medications that
can cause or exacerbate tremor, and the identification of a single
medication as causative is difficult, if not impossible. Differentiation
of medication-induced tremor (MIT) from other forms of tremor is
important and requires a thorough history and physical examination
of the patient. There are several important considerations in the
differential diagnosis of MIT: 1) exclusion of other medical causes of
tremor (e.g., hypoglycemia, hyperthyroidism); 2) a temporal relation
to the initiation of the drug is helpful; 3) a dose–response relationship
(i.e., increasing the medication dose worsens the tremor, or decreasing
the dose improves the tremor); and 4) lack of tremor progression,
unlike tremors in essential tremor (ET) or Parkinson’s disease (PD).1
MIT is also typically symmetrical, but in the setting of drug-induced
parkinsonism (DIP), a presentation with unilateral resting tremor is not
uncommon.2,3
Tremor can occur as a side effect of multiple medications in the
treatment of numerous diseases, making it very common in clinical
practice. MIT can range in severity from a minor nuisance in some to
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disabling in others. In some patients the tremor may not appear unless
an individual is predisposed to the tremor in question. There are mul-
tiple risk factors for MIT, with older age being the most important in
many studies.1 Tremor is well known to be more common in elderly
people, perhaps due to multiple medical problems that are treated with
numerous drugs. The interaction of patients’ underlying illnesses with
tremorogenic drugs is also important: for instance, metoclopramide-
induced parkinsonism is more severe in the setting of renal failure.4
Liver failure, metabolic derangements, and central nervous system
(CNS) pathology (e.g., traumatic brain injuries and infarcts) predispose
patients to MIT. Anxiety and mood states can also substantially affect
the manifestation of MIT. In some cases, treatment with medications,
such as dopamine-blocking agents (DBAs) or valproic acid, can reveal
underlying presynaptic dopamine deficiency and subclinical PD due to
loss of substantia nigra dopaminergic neurons.5,6
Polypharmacy plays a part in many instances of MIT. Interaction
of antiepileptics can result in raised serum drug concentrations (e.g.,
valproate) and tremor. Tremor due to medications is frequently tem-
porally associated with starting medication and can occur in the setting
of ‘‘therapeutic’’ blood levels as well as toxic states (e.g., lithium).7–9
Some common medications that can cause or enhance tremors include
amiodarone, antidepressants, b-adrenergic agonists, cyclosporine, DBAs,
lithium, tacrolimus, theophylline, and valproic acid.1 Multiple tremoro-
genic drugs can have additive effects (e.g., albuterol and theophylline in
patients with asthma).
In some settings it is prudent to watch and wait after starting a new
medication because many MITs can become less bothersome to a
patient or even improve over time.10–14 This would certainly apply if
a patient really needed to take a particular drug for their medical
condition (e.g., cyclosporine or tacrolimus in the setting of kidney
transplantation). Alternatively, a controlled-release preparation may
cause less tremor in a patient due to less peak-to-trough variability as
has been shown for controlled-release versions of valproic acid and,
more recently, tacrolimus.15,16 Luckily, the vast majority of MITs
respond to dose reduction or stopping the offending drug. Exposure
to toxic levels of certain drugs (e.g., ethanol, lithium, etc.) for longer
periods of time can lead to permanent tremors, especially if they affect
the cerebellum.
In this manuscript we will discuss insights into the pathophysiology
of tremor by highlighting proposed mechanisms of MIT for the
following better-known tremorogenic medications: amiodarone, amitrip-
tyline, b-adrenergic agonists, cyclosporine, DBAs, fluoxetine, lithium,
tacrolimus, theophylline, and valproic acid. Table 1 illustrates the
major tremorogenic drugs discussed in this paper and the phenom-
enology of the tremor seen with these different medications/drugs.
We will also briefly discuss tremors that can occur in withdrawal
states with certain drugs such as ethanol and propranolol. While the
frequency and epidemiology of MIT due to these drugs is fairly well
characterized, there are very few data on the mechanisms of how these
drugs induce tremors. MITs can originate from both central and
peripheral mechanisms, but it appears most MITs are a result of
enhancement in physiological tremor.
Methods
For this review, we first identified the major classes of drugs asso-
ciated with tremor and the most common offending drugs by class.1
We then searched PubMed on November 2016 for manuscripts using
the search terms ‘‘tremor’’ and the drug (or class of drug) of interest
Table 1. Common Medication-induced Tremors and Typical Tremor Phenomenology
Medication Class Action or Postural Tremor Intention Tremor Resting Tremor
Antiarrhythmics Amiodarone – Amiodarone
Antidepressants/mood stabilizers Amitriptyline, lithium, SSRIs Lithium Lithium, SSRIs
Antiepileptics Valproic acid – Valproic acid
b-Adrenergic agonists Albuterol, salmeterol Albuterol, salmeterol –
Chemotherapeutics Cytarabine Cytarabine –
Drugs of abuse Cocaine, ethanol Ethanol Cocaine, ethanol
Gastrointestinal drugs Metoclopramide – Metoclopramide, promethazine
Hormones Thyroxine, epinephrine Thyroxine, epinephrine –
Immunosuppressants Tacrolimus, cyclosporine Tacrolimus, cyclosporine –
Methylxanthines Theophylline – –
DBAs/dopamine depleters Haloperidol, tetrabenazine – Haloperidol, tetrabenazine
Abbreviations: DBA, Dopamine-blocking Agent; SSRI, Selective Serotonin Reuptake Inhibitor.
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with the following results: 1) valproic acid yielding 137 citations,
2) theophylline yielding 105 citations, 3) tacrolimus yielding 81 citations,
4) cyclosporine yielding 107 citations, 5) lithium yielding 255 citations,
6) amitriptyline yielding 49 citations, 7) tricyclic antidepressants yield-
ing 192 citations, 8) amiodarone yielding 33 citations, 9) beta-adrener-
gic agonists yielding 607 citations, 10) dopamine-blocking agents (DBAs)/
antipsychotics yielding 731 citations, and 11) selective serotonin reuptake
inhibitor yielding 267 citations.
We reviewed the titles of each of these papers for appropriateness
and eliminated all non-English language papers. We especially looked
for keywords in the title or abstract of these manuscripts that dealt
specifically with tremor and the mechanism of the tremor. Full papers
dealing with tremor due to medications of interest were obtained and
reviewed for this review. In some instances, additional manuscripts
were identified from these articles (if relevant) and pulled for review as
well. From our search and review, we focused on medications with the
most data: amiodarone, amitriptyline, b-adrenergic agonists, cyclos-
porine, DBAs, fluoxetine, lithium, tacrolimus, theophylline, and valproic
acid. We also reviewed a small amount of literature looking at drug
withdrawal states as a tremor-inducing situation and present our findings
in this setting.
Tremor phenomenology
In order to understand the phenomenology of MIT, discussed
below, we will briefly review the basics of tremors.17,18 Tremors are
typically characterized by rhythmic oscillations of a body part about
a joint and are best classified by the situation in which it occurs.
Two major categories of tremor are resting tremor and action tremor.
Resting tremor (as typically occurs in DIP or PD) is commonly 4–6 Hz
in frequency and occurs when the affected body part is fully supported
without ongoing voluntary muscle contraction. Action tremor, in
contrast, occurs with voluntary movement and can be divided into
postural tremor and kinetic tremor. Postural tremor occurs classically
when maintaining the arms in an outstretched position against gravity.
Kinetic tremor includes tremor that is task specific or with goal-
directed movements. Intention tremor is a subheading of kinetic
tremor that is a terminal kinetic tremor (as can be seen when nearing
the target on finger-to-nose testing). Finally, isometric tremor is a
kinetic tremor that occurs with active muscle contraction against a
fixed object.
The majority of MIT are posture holding or kinetic, but some
medications (especially lithium, DBAs, valproic acid) can cause resting
tremors. PD is a classic cause of resting tremor that typically occurs
unilaterally and improves with motion but can recur as re-emergent
tremor when a sustained posture is maintained. Resting tremor
typically worsens with distraction and goes away during sleep.
Physiological tremor is an action tremor that is mediated by both
central and peripheral mechanisms.17,18 It consists of low-amplitude,
high-frequency (8–12 Hz) oscillations depending on the stiffness, mass,
and other properties of the tremoring body part. The origins of
physiological tremor are from several sources including a mechanical
component (cardioballistics, subtetanic motor unit firing, and the
eigenfrequency), an 8–12 Hz central component, and in some cases an
enhancement of the mechanical component by short- and long-loop
reflexes.17,18 In situations where the motor units of a body part become
entrained and discharge in groups, physiological tremor becomes
enhanced physiological tremor (EPT).18 The segmental stretch reflex
plays an important role in EPT given it helps synchronize motor out-
flow to produce rhythmical contractions that reinforce the mechanical
properties of muscle spindle endings. EPT occurs with withdrawal
from ethanol, fever, anxiety, hyperthyroidism, hypoglycemia, shivering
due to cold, and other situations.18 Many MITs are proposed or
proven (amitriptyline) to occur by the mechanism of EPT.10 EPT has
the same central and peripheral components of physiological tremor,
but the 8–12 Hz central component and muscle stretch reflex play a
greater role in generation of the tremor. EPT can be very similar in
appearance and characteristics to ET when EPT becomes clinically
symptomatic.
Medication-induced tremors: background and pathophysiology
MIT is very common in clinical practice and we attempted to iden-
tify the major drugs (as above in Methods) associated with tremor and
the identified or proposed mechanism of tremorogenesis. We discuss
these drugs in alphabetical order by their major drug class.
Antiarrhythmics
Amiodarone. Amiodarone can cause ataxia, peripheral neuropathy,
and tremor in cardiac patients treated for arrhythmias.19–22 The
tremor due to amiodarone may have multiple etiologies. Amiodarone
is a class III antiarrhythmic, and tremor has been reported by about
a third of patients who take this drug.19 Amiodarone-induced tremor
is postural and intentional, and typically is in the 6–10 Hz range.19
There are also rare reports of a Parkinsonian resting tremor with
amiodarone therapy.23 Amiodarone-induced tremor is dose depen-
dent, may emerge at any time during therapy, and typically improves
within several weeks after dose reduction or discontinuation.19 Main-
tenance of the dose at 200 mg daily seems to minimize side-effects
while providing good arrhythmia control.22
The mechanism of amiodarone-induced tremor is unknown. Amio-
darone is known to cross the blood–brain barrier, but amiodarone and
its active metabolite, desethylamiodarone, were only detected in the
brain at very low levels relative to the lung, pancreas, and adipose
tissue.24 Given that amiodarone can cause hypothyroidism and hyper-
thyroidism, it is important to rule out hyperthyroidism as a cause of
tremor in amiodarone-treated patients. This potential mechanism of
causing tremor by inducing hyperthyroidism is unique to amiodarone
(outside thyroxine or other thyroid hormone therapy, of course).
Propranolol reduced tremor in two patients on chronic amiodarone
therapy who had bothersome tremors despite lowering of the amio-
darone dose.19
Recent research indicates that the incidence of amiodarone-induced
neurological side effects may be considerably lower than the third or
more of patients reported by some authors. Orr and Ahlskog25 found
that only 2.8% of patients treated with amiodarone in the recent Mayo
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Clinic experience developed a neurotoxic side effect and they related
this lower incidence of tremor and other side effects to lower doses
(now 200 mg per day) of amiodarone in practice over time compared
to the past.
Antidepressants/mood stabilizers
Amitriptyline. Tricyclic antidepressants are useful drugs for many dis-
orders, including neuropathic pain, headaches, and depression. In a
study nearly 40 years ago, amitriptyline was noted to cause a disabling
postural and action tremor of the hands in some patients.26 Postural
tremor may lead to discontinuation of amitriptyline therapy in a few
treated patients, but in many cases amitriptyline-induced tremors can
improve over time while patients remain on therapy.10–13
While most MITs are due to an uncharacterized mechanism,
it appears amitriptyline accentuates the central component of physiolo-
gical tremor.10 In this study, patients were evaluated for tremor before
and after starting amitriptyline for depression or chronic pain syndro-
mes. Fifteen subjects were enrolled and studied with accelerometry and
forearm flexor/extensor electromyography (EMG). While there was
only an obvious clinical change in approximately one-third of patients
treated with amitriptyline, there was an increase in the spectral power
of tremor in all 15 subjects by electrophysiological measures.10 EMG
frequencies were in the 8–18 Hz range while accelerometer frequen-
cies were in the 6–11 Hz range and did not change. The frequency
bands of significant coherence corresponded with the EMG frequen-
cies and were independent of changes to the hand’s resonant frequency
by added inertia, indicating the enhanced tremor came from a central
process, not a peripheral one.10 The authors concluded that the
increase in the EMG–EMG coherence was indicative of increased
drive to the motor units by central mechanisms and by their report this
was the first demonstration of enhancement by any drug of the central
component of physiological tremor.10
Selective serotonin reuptake inhibitors. Selective serotonin reuptake
inhibitors (SSRIs) are very commonly prescribed to treat depression
and anxiety, largely replacing tricyclic antidepressants in the treatment
of these illnesses. While numerous movement disorders have been
reported with SSRIs, tremor is probably the most common movement
disorder induced by these drugs.27,28 Approximately 20% of patients
started on SSRIs develop tremor without having a previous history
of tremor. Serrano-Dueñas29 described 21 patients who developed
fluoxetine-induced tremors on a mean dose of 26 mg daily. Tremors
were typically postural or action in nature, 6–12 Hz, and emerged
1–2 months after therapy began. Tremor remitted within 1 month
after discontinuation of fluoxetine in 10 patients, although it persisted
for at least 15 months in the other 11 patients.29
The mechanism for SSRI-induced tremor is unknown, but Serrano-
Dueñas has hypothesized that the tremor is due to stimulation of
serotonergic receptors found in the inferior olive.29 He also proposed
that overexcitation of the red nucleus and the inferior olivary nuclei
could lead to overstimulation of thalamic and cortical neurons and
resultant tremor. There is evidence that antagonism at 5HT1c, 5HT2,
and 5HT3 receptors by clozapine results in reduction of ET, indicat-
ing a possible role of serotonin in the generation or exacerbation
of tremor.30
In the harmaline-induced tremor model in rats, citalopram was
also shown to exacerbate tremors.31 Pretreatment with citalopram,
in a dose-dependent fashion, exacerbated the intensity, duration, and
amplitude of harmaline-induced tremor on EMG.31 There was also a
significant decrease in serotonin turnover (5HIAA/5HT ratio) in the
brain stem suggesting a possible role of serotonergic impairment in
citalopram’s augmentation of harmaline-induced tremor. The authors
suggested that reduction in serotonergic neurotransmission in the brain-
stem (inferior olive) is potentially the mechanism for tremor exacerbation
in this model.31
Serotonin syndrome can occur with SSRIs and other drugs.32
Tremor is commonly an early manifestation in mild and moderate
cases of this syndrome, and is more prominent in the legs.32 SSRI
withdrawal syndrome is also characterized by tremulousness, irrit-
ability, anxiety, and paresthesias.33 This syndrome can occur during
withdrawal from any SSRI, but is probably more common with SSRIs
with shorter half-lives, such as paroxetine.33
Lithium. Lithium-induced tremor is perhaps one of the most commonly
encountered MITs in clinical practice.7–9 Approximately 27% of
patients treated with lithium developed tremors in one review, with
individual studies showing a wide range of variability from 4% to
65%.8 Unlike tricyclic antidepressant-related tremor, one study found
that 32% of patients felt that lithium-related tremor caused some
disability or resulted in non-compliance with therapy.9 For most patients
on chronic lithium therapy the tremor is usually mild and not disabling,
however. Lithium-induced tremor occurs most often in elderly patients
and appears to be more common in men than women.14,34–37
Lithium-induced tremor is typically in the 8–12 Hz range, thereby
falling into the category of, EPT and it mainly affects the hands.7
Tremor can occur over a wide range of lithium concentrations with
a correlation to lithium dose possible in some patients.37 Certain
concomitant drug therapies such as tricyclic antidepressants, SSRIs,
or valproic acid can potentiate lithium-related tremor.7,38 As with
amitriptyline-induced tremor, lithium-induced tremor can improve
over time with continued therapy.14
Rarely, lithium can cause DIP and resting tremor in some treated
patients; however, this can frequently improve with a reduction in dose
of lithium.7,39 Lithium can sometimes cause long-standing cerebel-
lar tremor in the setting of toxicity as another potential mechanism of
tremorogenesis.7
The exact mechanism of lithium-induced tremor is unknown but
reduction of the dose or discontinuance of the drug usually leads to
improvement.7–9 Lithium-induced tremor has actually never been
properly studied for potential mechanisms of causation. It does appear
however that brain levels of lithium are related to the presence of tre-
mor and by most accounts lithium-induced tremor is thought to arise
from the central nervous system. Like with SSRIs, it is hypothesized
that there may be effects on brainstem serotonergic neurons or other
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effects on potential central oscillators.7–9 There is some evidence from
animal studies with other serotonergic agents such as SSRIs supporting
this hypothesis. Some authors, however, have found that lithium-
induced tremor was not influenced by the serotonergic affinity of the
antidepressants that were added to the therapeutic regimen. In addi-
tion, b-adrenergic antagonists can help lithium-induced tremor and
the non-selective b-adrenergic antagonist, propranolol, appears to be
most effective.7–9
Recent work in the laboratory has shown that lithium treatment in
mice lowers brain tau levels and increases substantia nigra and cortical
iron, which is closely associated with neurodegeneration, cognitive loss,
and Parkinsonian features.40 These changes may explain why some
tremors and parkinsonism may develop in lithium-treated patients
over time.
Antiepileptics
Valproic acid. Valproic acid is an older antiepileptic that is very com-
monly used for migraine prophylaxis, seizures, and mood stabilization.
This medication, like lithium, is one of the most commonly seen MIT
in practice, even today.41,42 Similar to SSRIs, up to 80% of patients
treated with valproic acid may show evidence of tremor on accelero-
metry recordings with perhaps only 25% of patients complaining of
tremor.41–44 The tremor is typically with action, but can occasionally
occur at rest as well. The tremor appears to be dose related and can
improve with dose reduction, usually abating within several weeks.
Tremor amplitude appears to be more pronounced with immediate
release preparations relative to controlled-release preparations, perhaps
due to greater peak-to-trough variation in drug levels.15
The clinical and electrophysiological features of valproic acid-induced
tremor appear typical of EPT given treated patients had a reduction in
their tremor frequency by 3 Hz or more by weight loading.15,45 This is
typical of an alteration in the frequency of the mechanical component of
physiological tremor.
Valproic acid has multiple mechanisms of action including reduction
of high-frequency neuronal firing of sodium-dependent action potentials,
as well as increasing GABAergic neurotransmission.15,41–47 Two other
antiepileptics that improve ET (gabapentin and topiramate) also increase
GABAergic neurotransmission, so these mechanisms of action are
unlikely to be the cause of valproic acid-induced tremor.
If dose reduction or switching to a controlled-release preparation is
not possible, then acetazolamide, amantadine, or propranolol may
provide some benefit for the tremor.46,47 Valproic acid can also cause
parkinsonism in the setting of antiepileptic therapy or mood stabi-
lization and clinicians should be aware of this as well.6,48 In mice, there
is some evidence that valproic acid might be toxic to dopaminergic
neurons.49
b-Adrenergic agonists
Perhaps one of the best-known MIT is that associated with b-adrenergic
agonists. Epinephrine and norepinephrine are endogenous non-selective
adrenergic agonists that are associated with sympathetic activation and the
‘‘fight or flight response.’’ Sympathomimetics are commonly used in
practice with inhaled b-adrenergic agonists in wide use for respiratory
illnesses.50 Albuterol, salmeterol, and formoterol are perhaps most
commonly used in the United States, with albuterol considered shorter
acting (lasting 6 hours or less) and salmeterol and formoterol longer
acting (up to 12 hours).50 Fortunately for patients, tolerance to sympa-
thomimetic drugs can develop over time.
Although the exact mechanism for tremor induction by b-adrenergic
agonists is unknown, there is some evidence that b-adrenergic agonists act
directly on muscle.51,52 A classic experiment by Foley et al.51 demon-
strated that when subjects were ischemically prevented from receiving
an infusion of epinephrine in their arm, tremor did not occur in the limb.
In another experiment by Young et al.,53 normal and ET subjects
receiving intra-arterial injection of the b-adrenergic agonist isoproterenol
into one arm experienced an increase in tremor amplitude of approxi-
mately 2.7-fold relative to baseline. Intravenous or intra-arterial injection
of propranolol reduced the enhanced action tremor in both normal and
ET subjects, but ET subjects with postural tremor were unaffected by
the infusion of propranolol.53 The authors proposed that ET likely has
another mechanism generating the tremor beyond peripheral mechanism
and now it is known that this tremor has a central generator that has not
been precisely localized in the cerebello-thalamo-cortical circuit.17,18
b2-Adrenergic receptors are located on the plasma membranes of
extrafusal fibers and muscle spindles. Stimulation of these receptors by
b-adrenergic agonists is thought to enhance physiological tremor by
sensitizing muscle spindles and c-fibers with subsequent synchroniza-
tion of the afferent volley to the CNS.17,18,54 More recent data indicate
that the b-adrenergic agonist salbutamol and the non-selective b-adrenergic
receptor blocking agent propranolol may both affect corticomuscular
coherence and tremor partially through a CNS action.55
Dopamine-blocking agents
DBAs are commonly used in psychiatric practice for psychosis (neu-
roleptics) or as adjunctive therapy for mood disorders. They are also
commonly used in the setting of gastroparesis (metoclopramide) or
nausea (prochlorperazine, promethazine). Dopamine-depleting agents
such as tetrabenazine can also cause tremor and parkinsonism by
reversibly depleting dopamine through VMAT2 transporter inhibition.
Typically, the effectiveness of DBAs is correlated with D2 dopamine
receptor blockade. Clozapine and the novel antipsychotic pimavanserin
challenge this notion and are unlike most DBA in that their effectiveness
in treating psychosis is correlated with antagonism (clozapine) or inverse
agonism (pimavanserin) at 5HT2A (serotonergic) receptors.
56
The mechanism of DBA causing tremor appears to be due to blockade
of dopamine receptors, disrupting normal nigrostriatal dopaminergic
neurotransmission. Parkinsonian resting tremor appears to have origins in
the cerebello-thalamo-cortical circuit and in the basal ganglia receiving
areas of the thalamus (the ventralus intermedius (VIM)).17,18,57 Tremor
severity in PD doesn’t correlate with loss of dopamine in the nigrostriatal
pathway, however.17 Depletion of dopamine leads to increased firing
of globus pallidus internus (GPi) neurons releasing GABA thereby leading
to a net hyperpolarization of neurons in the thalamus. Dopaminergic
medications ameliorate this abnormal hyperpolarization of thalamic
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neurons by the GPi by restoring a better balance between the direct and
indirect pathways in the basal ganglia. It appears from recent research
that both the subthalamic nucleus (STN) and the thalamus may have
pacemaking abilities in PD-related tremor.57
As mentioned previously, resting tremor in DIP due to DBA can
be asymmetric in many patients.2–5 Treatment of MIT due to DBA
is aimed at reducing the dose of the offending drug or attempting to
eliminate it completely. In many suspected DIP cases, however, treat-
ment with DBA may unmask presynaptic dopamine deficiency due to
an underlying Parkinsonian syndrome.58 In these patients, symptoms
will continue and even progress after the DBA is withdrawn despite
perhaps some initial improvement. If this is not possible then anticho-
linergics or amantadine are often used to combat symptoms. Tardive
tremor can also occur after extended periods on neuroleptic therapy.58
Tardive tremor is distinct from resting tremor in DIP given that tardive
tremor improves with neuroleptic therapy or dopamine-depleting ther-
apy.59 Tardive tremor is larger in amplitude than Parkinsonian tremor
and can interfere with activities of daily living.59 A recent report by
Rodrigues et al.60 demonstrated that resting tremor and postural tremor
in the setting of DIP caused by aripiprazole were responsive to thalamic
deep brain stimulation. This is similar to findings in PD where deep brain
stimulation of the VIM nucleus of the thalamus, subthalamic nucleus, or
GPi can improve resting tremor.
Immunosuppressants
Cyclosporine and tacrolimus are calcineurin inhibitors that are com-
monly used in immunosuppressive regimens for liver and kidney trans-
plantation. Both drugs commonly cause tremors that appear to be due
to enhancement of physiological tremor.61
Cyclosporine. Up to 40% of patients taking cyclosporine will have
neurological side effects including tremors, headache, paresthesias,
seizures, encephalopathy, visual disorders, or other symptoms.62–64
With this diffuse set of neurological symptoms and signs, there has
been significant effort in trying to delineate the mechanism for these
neurological problems. Tremor is the most common neurological
adverse event and can occur in 20–40% of patients depending upon
the clinical setting.62–64 It appears that patients treated chronically
with cyclosporine tend to have a mild postural tremor that typically
does not significantly interfere with daily activities.62–64 Many patients
historically will relate a history of mild tremor during the earlier course
of treatment, but after some time the tremor has abated or improved,
similar to many MITs. Toxic states and higher blood levels are
associated with more patient complaints and perhaps larger tremor
amplitude.61–64 Interestingly, in a single case report, a 37-year-old
female who was labeled with ET exacerbated by cyclosporine therapy
following renal transplantation safely and successfully underwent
thalamic deep brain stimulation surgery without infections and with
good response.65
There are numerous possible mechanisms for cyclosporine-induced
tremor, but the tremor appears typical of EPT in its characteristics
given a shift in the dominant EMG frequency to a lower frequency
with weighting.61 Cyclosporine has effects on dopaminergic neuro-
transmission and it may influence receptor physiology, phosphoryla-
tion pathways, and transcription as well.62–65 A recent study in pigs
demonstrated gross normal brain pathology after chronic treatment
with low-dose cyclosporine; however, on histological examination, there
were signs of neuronal, perivascular, and meningeal granulocytic and
mononuclear infiltrates in one of the five pigs.66
Tacrolimus. Tremor was reported with tacrolimus in the first reports of
neurological toxicity related to the drug after liver transplantation.67,68
Eight of 22 pediatric and 10 of 44 adult patients undergoing orthotopic
liver transplantation reported tremor with tacrolimus therapy.67,68 The
tacrolimus-associated tremor described in the 10 adult patients was
severe, worsened with action, and affected the hands, interfering with
handwriting.67 Dose reduction reduced the tremor, although several
patients continued to have mild, non-bothersome tremor.67 Tremor
due to tacrolimus therapy also occurs in other disease states with
9% (81/896) of rheumatoid arthritis patients reporting tremor in one
study.69
As with controlled-release valproic acid, recent data indicate that
reducing peak-to-trough variability by using a controlled-release prepa-
ration of tacrolimus can reduce tremor in kidney transplant recipients
experiencing tremor with immediate-release tacrolimus.16 This modifica-
tion also improved tremor amplitude with posture holding and improved
tremor-related quality of life.16
Methylxanthines
Theophylline. Theophylline is an adenosine-2A receptor antagonist and
may provide benefit in PD similar to other adenosine-2A antagonists
such as istradefylline, caffeine, and tozadenant.70 In a small crossover
trial in PD, however, theophylline appeared to cause more tremor in the
treatment of PD patients when levodopa was withdrawn.71 Intravenous
aminophylline also caused more power in the accelerometer measure-
ment of tremor in patients with ET and in those with tremor related
to hyperthyroidism.72,73 Theophylline also increases tremor power in
the typical physiological frequency (8–12 Hz) in euthyroid normal
individuals.73
The exact mechanism of theophylline-induced tremors is largely
unknown, but is likely a result of enhancement of physiological tremor.
It is known that theophylline has the ability to mobilize intracellular
calcium, antagonize adenosine receptors, and also may produce a
slight rise in catecholamine levels in the central nervous system.72,73
Any of these mechanisms may be at play, but the slight rise in cate-
cholamine levels in the CNS is thought to be too minimal to affect a
tremulous response.
Withdrawal states and toxin-induced tremors
Tremors can occur in the setting of withdrawal states, especially
with benzodiazepines, ethanol, and opiates. One well-performed study
found that patients undergoing ethanol withdrawal had tremors in the
range of 8–12 Hz.74 When patients abruptly stop b-adrenergic anta-
gonists such as propranolol, an increase in action and postural tremor
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can be observed as well. Even 1 month after discontinuing pro-
pranolol, increased tremor power was observed in subjects without
underlying tremor disorders who were being treated for cardiac
conditions.75 Most withdrawal-related tremors appear typical of EPT
as with most MIT.
When toxic levels of certain medications (such as lithium, phenytoin,
or the chemotherapeutic cytarabine) and some drugs of abuse (ethanol)
are experienced by patients, cerebellar damage can ensue and this can
lead to a prominent and sometimes permanent cerebellar/intention
tremor.7–9,76 Cytarabine appears toxic to Purkinje cells especially in
the lateral cerebellar hemispheres.76 Chronic ethanol abuse can also
cause anterior vermis and lateral hemisphere damage to many cell
types including Purkinje cells and cause a similar tremor.77
Summary and future directions
MITs are common in clinical practice, occur with many medica-
tions, and are often very treatable by reducing the dose of the drug,
switching to a controlled-release preparation, or switching to another
agent. In some cases, it is not possible to reduce the dose of the
offending agent and additional medication (e.g., propranolol) may be
necessary to try and treat the tremor. In rare instances where clinically
appropriate, deep brain stimulation surgery may be necessary to
ameliorate the tremor.
The vast majority of tremors that are diagnosed as MIT are
mechanistically due to EPT, but clinicians should beware that a patient
may have underlying ET or PD that is unmasked when treated with an
exacerbating agent.17,18 They should also beware of the very unusual
case with amiodarone, which can cause tremor by inducing hyper-
thyroidism in addition to its own mechanism of inducing tremor. In
the case of DIP, an [123I]-ioflupane scan (DATSCAN) can be very
revealing, in some cases demonstrating loss of striatal dopamine
transporter binding in subjects that would have been diagnosed with
DIP when they actually have underlying PD.5
EPT is by far the most common mechanism of tremor generation by
medications17,18 (Table 2). Physiological tremor has many components
that can be influenced by medications with some influencing the cen-
tral component (amitriptyline) and others altering the peripheral
component (b-adrenergic agonists, cyclosporine, etc.). Other mechan-
isms include blockade of dopaminergic neurotransmission in the
nigrostriatal pathway by DBA or dopamine-depleting agents. Cere-
bellar damage due to longstanding abuse (ethanol) or toxic states can
also cause intention tremors that can be quite bothersome.
It is interesting to note that Raethjen et al.10 published the first work
that demonstrated a definitive effect on the central component of phy-
siological tremor by any drug (amitriptyline) in 2001. In addition, recent
work on valproic acid and theophylline demonstrating these drugs cause
tremor by likely enhancing physiological tremor is relatively new as
well.15,45,61 There is significant need for further mechanistic delineation
of how many tremorogenic drugs enhance physiological tremor or cause
tremor by other mechanisms.
Finally, it will be important to further define the most vital anatomical
structures for the generation of tremor in the CNS and further under-
stand the physiology of these interconnected players. It will also be
important to develop further knowledge of neurotransmitters and their
Table 2. Mechanisms of Medication-induced Tremor for More Common Offending Agents
Medication/Drug Mechanism(s) Reference(s)
Amiodarone Likely EPT, possible hyperthyroidism in some 19,23,25
Amitriptyline EPT (enhances central component) 10
b-Adrenergic agonists EPT (enhance the mechanical reflex component) 51–55
Cyclosporine EPT (enhances peripheral component) 60
Cytarabine Cerebellar toxicity to Purkinje cells 75
DBA Blockade of striatal dopamine receptors 17,18,57,58
Ethanol EPT in withdrawal states
Cerebellar toxicity in alcoholism
73,76
Lithium Likely EPT 7–9,38
SSRIs Likely EPT 29
Tacrolimus EPT (enhances peripheral component) 60
Theophylline Likely EPT 71,72
Valproic acid EPT? dopaminergic dysfunction as well 15,48
Abbreviations: DBA, Dopamine-blocking Agent; EPT, enhanced physiological tremor; SSRIs, Selective Serotonin Reuptake Inhibitor
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receptors that may influence tremor or actually suppress it. Hopefully
this further knowledge will lead to better therapeutics for pathological
tremors and allow us to develop less tremorogenic drugs.
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